Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations

@article{Gambarin2009RationaleAD,
  title={Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations},
  author={F. Gambarin and V. Favalli and A. Serio and M. Regazzi and M. Pasotti and C. Klersy and R. Dore and S. Mannarino and M. Vigan{\'o} and A. Odero and S. Amato and L. Tavazzi and E. Arbustini},
  journal={Journal of Cardiovascular Medicine},
  year={2009},
  volume={10},
  pages={354–362}
}
Background The major clinical problem of Marfan syndrome (MFS) is the aortic root aneurysm, with risk of dissection when the root diameter approximates 5 cm. In MFS, a key molecule, transforming growth factor-β (TGF-β), normally bound to the extracellular matrix, is free and activated. In an experimental setting, TGF-β blockade prevents the aortic root structural damage and dilatation. The angiotensin receptor 1 blockers (sartanics) exert an anti-TGF-β effect; trials are now ongoing for… Expand
68 Citations
An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome.
  • 2
Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
  • 20
  • PDF
Atenolol versus losartan in children and young adults with Marfan's syndrome.
  • 321
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
...
1
2
3
4
5
...